Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting

Usami,Eiseki; Kimura,Michio; Iwai,Mina; Takenaka,Shoya; Teramachi,Hitomi; Yoshimura,Tomoaki

doi:10.3892/mco.2016.738

Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting

Authors:
- Eiseki Usami
- Michio Kimura
- Mina Iwai
- Shoya Takenaka
- Hitomi Teramachi
- Tomoaki Yoshimura
View Affiliations

Affiliations: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki‑shi, Gifu 503‑8502, Japan, Clinical Pharmacy, Gifu Pharmaceutical University, Gifu‑shi, Gifu 501‑1196, Japan
Published online on: January 25, 2016 https://doi.org/10.3892/mco.2016.738
Pages: 591-596

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen is considered to be a standard treatment for non‑Hodgkin's lymphoma (NHL). Patients receiving CHOP chemotherapy often experience febrile neutropenia (FN) due to myelotoxicity. The proper management of FN is essential to guarantee a positive outcome of the NHL treatment. Therefore, the present study retrospectively examined chemotherapy continuity and the incidence of FN during CHOP therapy in an outpatient setting. The subjects were 136 patients who received CHOP chemotherapy between January 2012 and December 2014. A total of 31 patients unable to be treated in an outpatient setting were excluded from the study. Of the remaining 105 patients, 73 patients who did not require hospitalization during the chemotherapy treatment were included in the non‑hospitalized group, and 32 patients who required hospitalization during chemotherapy treatment were included in the re‑hospitalization group. The numbers of patients from these two groups who completed the planned treatment were 71 and 24, respectively (P<0.01). In addition, the duration of granulocyte‑colony stimulating factor (G‑CSF) treatment was 5.3±1.22 and 6.1±1.46 days, respectively (P<0.01). The numbers of patients experiencing FN in an outpatient setting were 14 and 19, respectively (P<0.01). During administration of primary prophylaxis with G‑CSF, the incidence of FN was 21.0% (22/105) in cycle 1. In conclusion, the present study has revealed a requirement to educate patients about infection prevention prior to the first cycle of chemotherapy. Patients who require the administration of long‑ term G‑CSF are at risk of unplanned re‑hospitalization, and treating them with polyethylene glycol G‑CSF to reduce the number of required injections should be considered as an option. Therefore, proper supportive therapy and management of infection are important to safely treat patients with CHOP in an outpatient setting.

View Figures

View References

1	Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M and Verhoef G: Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 87:277–283. 2008. View Article : Google Scholar : PubMed/NCBI
2	Pettengell R, Schwenkglenks M and Bosly A: Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol. 87:429–430. 2008. View Article : Google Scholar : PubMed/NCBI
3	Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 29A:319–324. 1993. View Article : Google Scholar : PubMed/NCBI
4	Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, et al: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 47:8–32. 2011. View Article : Google Scholar : PubMed/NCBI
5	Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ and Fridman M: OPPS Working Group and ANC Study Group: Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 44:2069–2076. 2003. View Article : Google Scholar : PubMed/NCBI
6	Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R, Constenla M and Schwenkglenks M: Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU): Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: Data from the INC-EU prospective observational European neutropenia study. Br J Haematol. 144:677–685. 2009. View Article : Google Scholar : PubMed/NCBI
7	Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 24:3187–3205. 2006. View Article : Google Scholar : PubMed/NCBI
8	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
9	Armitage JO: Staging non-Hodgkin lymphoma. CA Cancer J Clin. 55:368–376. 2005. View Article : Google Scholar : PubMed/NCBI
10	Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, et al: The European Organisation for Research and EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 42:2433–2453. 2006. View Article : Google Scholar : PubMed/NCBI
11	Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based, clinical practice guideline. J Clin Oncol. 24:3187–3205. 2006. View Article : Google Scholar : PubMed/NCBI
12	Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L and Ershler WB: Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 12:1416–1424. 2007. View Article : Google Scholar : PubMed/NCBI
13	Case DC Jr, Desch CE, Kalman LA, Vongkovit P, Mena RR, Fridman M and Allen B: Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients. Clin Lymphoma Myeloma. 7:354–360. 2007. View Article : Google Scholar : PubMed/NCBI
14	Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D and Lyman GH: Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: The results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 6:109–118. 2008.PubMed/NCBI
15	Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M, Szucs TD and Jackisch C: Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU): Neutropenia occurrence and predictors of reduced chemotherapy delivery: Results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 16:1299–1309. 2008. View Article : Google Scholar : PubMed/NCBI
16	Salar A, Haioun C, Rossi FG, Duehrsen U, Pettengell R, Johnsen HE, Jaeger U, Verhoef G, Schwenkglenks M, Bacon P, et al: The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice. Leuk Res. 36:548–553. 2012. View Article : Google Scholar : PubMed/NCBI
17	Mayordomo JI, López A, Viñolas N, Castellanos J, Pernas S, Alonso Domingo J, Frau A, Layola M, Antonio Gasquet J and Sánchez J: ENIA Study Group: Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin. 25:2533–2542. 2009. View Article : Google Scholar : PubMed/NCBI
18	Lyman GH and Delgado DJ: Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 98:2402–2409. 2003. View Article : Google Scholar : PubMed/NCBI
19	Morstyn G, Foote MA, Walker T and Molineux G: Filgrastim (r-metHuG-CSF) in the 21st century: SD/01. Acta Haematol. 105:151–155. 2001. View Article : Google Scholar : PubMed/NCBI
20	Lord BI, Woolford LB and Molineux G: Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clin Cancer Res. 7:2085–2090. 2001.PubMed/NCBI